Prospektive, longitudinale, dosiseskalierende, randomisierte Phase- I/II- Studie mit Iscador QuFrF und Iscador Qu Spezial mit HIV- Positiven, Krebspatienten und gesunden, nichtrauchenden Probanden

Journal/Book: Forsch. Komplementärmed. 3 (4), 169-175. 1996;

Abstract: English title: "Prospective, Longitudinal, Dose-Escalating, RandomisedPhase I/II Study with Iscador QuFrF and Iscador Qu Spezial in HIVPositives, Cancer Patients and Healthy, Non-Smoking Individuals". In aphase I/II trial with Iscador Qu Spezial in HIV positives, healthynon-smoking volunteers and cancer patients, possible toxic side effects,immunomodulating and anti-HIV activities were studied. Iscador QuFrF andIscador Qu Spezial were tolerated quite well and no toxicities could bedocumented. In almost all HIV positives, CD4% was stable over theobservational period of 15 months. The CD4/CD8 ratio stayed equallystable in all groups. CD3/25-positive lymphocytes, as measure of IL-2production, increased and were significant in all groups. Iscador QuFrFand Iscador Qu Spezial had similar effects on the production of IL-2. Ingroup A with HIV positives, there was a decline of beta-2 microglobulinat 5 mg and maximum dose. In groups B and C, beta-2 microglobulin stayedstable. In several cases, there was a decline in p24 antigen. Clinicallynone of the HIV positives' clinical condition deteriorated during the 15months duration of the study, and in 35 out of 46 (76%) patients,quality of life increased.COPYRIGHT BY Medical Information Service, British Library END OF DOCUMENT

Keyword(s): DRUG-THERAPY

Zurück | Weiter